Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations

Conclusions TAS-121 was well tolerated up to the MTD and demonstrated antitumor activity in Japanese T790M-positive NSCLC patients.Clinical trial registration: JapicCTI-142651.

Source: Investigational New Drugs - February 21, 2019 Category: Drugs & Pharmacology Source Type: research